OCADLIKOVA, DARINA
 Distribuzione geografica
Continente #
NA - Nord America 2.341
AS - Asia 1.757
EU - Europa 1.462
AF - Africa 107
SA - Sud America 92
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.767
Nazione #
US - Stati Uniti d'America 2.298
SG - Singapore 514
VN - Vietnam 460
CN - Cina 378
GB - Regno Unito 355
SE - Svezia 261
IT - Italia 219
DE - Germania 159
IN - India 107
HK - Hong Kong 91
FR - Francia 81
BR - Brasile 66
RU - Federazione Russa 61
NL - Olanda 57
IE - Irlanda 56
UA - Ucraina 44
FI - Finlandia 39
ZA - Sudafrica 36
KR - Corea 33
BG - Bulgaria 32
JP - Giappone 28
BD - Bangladesh 27
CA - Canada 26
JO - Giordania 25
CI - Costa d'Avorio 23
BE - Belgio 21
EE - Estonia 20
TG - Togo 17
TH - Thailandia 16
AR - Argentina 13
ID - Indonesia 13
PH - Filippine 12
TR - Turchia 11
SC - Seychelles 10
CH - Svizzera 9
AT - Austria 8
MX - Messico 8
PL - Polonia 8
ES - Italia 7
EG - Egitto 6
LB - Libano 6
PK - Pakistan 6
RO - Romania 6
IQ - Iraq 5
NG - Nigeria 5
CL - Cile 4
CZ - Repubblica Ceca 4
AU - Australia 3
IR - Iran 3
KZ - Kazakistan 3
LT - Lituania 3
MY - Malesia 3
NZ - Nuova Zelanda 3
OM - Oman 3
PE - Perù 3
SA - Arabia Saudita 3
SN - Senegal 3
CO - Colombia 2
CR - Costa Rica 2
ET - Etiopia 2
GR - Grecia 2
JM - Giamaica 2
KG - Kirghizistan 2
NO - Norvegia 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TN - Tunisia 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BF - Burkina Faso 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EU - Europa 1
HN - Honduras 1
HU - Ungheria 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LV - Lettonia 1
MA - Marocco 1
MU - Mauritius 1
NP - Nepal 1
PR - Porto Rico 1
QA - Qatar 1
SI - Slovenia 1
SR - Suriname 1
UY - Uruguay 1
VE - Venezuela 1
Totale 5.767
Città #
Singapore 368
Southend 322
Ashburn 243
Fairfield 222
Chandler 210
San Jose 135
Ho Chi Minh City 112
Wilmington 93
Ann Arbor 91
Santa Clara 89
Hanoi 88
Woodbridge 85
Houston 84
Hong Kong 83
Seattle 77
Princeton 72
Cambridge 60
Dublin 55
Bologna 50
Beijing 46
Boardman 44
Hefei 40
New York 36
Helsinki 33
Lauterbourg 32
Sofia 32
Nanjing 27
Tokyo 27
Westminster 27
Los Angeles 26
Amman 25
Seoul 24
Abidjan 23
Dong Ket 23
Padova 23
Brussels 21
Jacksonville 20
Buffalo 19
Council Bluffs 19
Jinan 17
Lomé 17
Berlin 16
Frankfurt am Main 16
Hyderabad 16
San Diego 16
Redwood City 15
Da Nang 14
Pune 14
Dallas 13
Haiphong 13
Milan 13
Toronto 13
Redondo Beach 12
Shenyang 12
São Paulo 12
Chicago 11
Jakarta 11
Hebei 10
Nuremberg 10
San Francisco 10
Bangkok 9
Bremen 9
Guangzhou 9
London 9
Benevento 8
Bern 8
Changsha 8
Johannesburg 8
Orem 8
Tianjin 8
Yubileyny 8
Amsterdam 7
Atlanta 7
Phoenix 7
Redmond 7
Rome 7
Shanghai 7
Turin 7
Dhaka 6
Florence 6
Mülheim 6
Nanchang 6
Ninh Bình 6
Warsaw 6
Wuhan 6
Zhengzhou 6
Biên Hòa 5
Hamm 5
Shenzhen 5
Abeokuta 4
Cairo 4
Dearborn 4
Gradara 4
Hangzhou 4
Hải Dương 4
Jiaxing 4
Medford 4
Montreal 4
Munich 4
New Delhi 4
Totale 3.635
Nome #
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 258
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. 235
ATP release from chemotherapy-treated dying leukemia cells Elicits an immune suppressive effect by increasing regulatory T cells and Tolerogenic dendritic cells 230
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 220
Immunosenescence and immunotherapy in elderly acute myeloid leukemia patients: Time for a biology-driven approach 216
Flow cytometry analysis of T-cell subsets in cerebrospinal fluid of narcolepsy type 1 patients with long-lasting disease 210
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. 208
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 208
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 204
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 199
The more, the better: "Do the right thing" for natural killer immunotherapy in acute myeloid leukemia 198
Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia 190
PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response 186
The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. 186
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 185
Extracellular ATP exerts opposite effects on activated and regulatory CD4 + T cells via purinergic P2 receptor activation 180
Immune characterization in Narcolepsy Type 1. 170
Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells 165
In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells. 159
Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies. 157
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients 152
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 152
Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade 148
Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma – Phase II study results 141
Flow cytometry T cell profiling in a recent-onset narcoleptic type 1 child: a case report 140
Isolation and expansion of allogeneic myeloma-specific interferon-gamma producing T cells for adoptive immunotherapy. 139
Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma. 138
Selective depletion of alloreactive T cells and study of anti-tumor activity of specific T cell clones in patients with leukemia. 133
Generation of dendritic cells using cell culture bags--description of a method and review of literature. 130
The preparation of anticancer vaccine for patients with multiple myeloma on the base of monoclonal immunoglobulin loaded dendritic cells. 130
Dendritic cell counts and their subsets during treatment of multiple myeloma. 128
Release of IFNg by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells 123
The preparation of myeloma-specific T cells activated with dendritic cells loaded with nonapeptides derived from mucin protein MUC1 and catalytic subunit of telomerase hTERT. 110
A screening of antineoplastic drugs for acute myeloid leukemia reveals contrasting immunogenic effects of etoposide and fludarabine 95
Noncanonical NF-κB signaling in dendritic cells is required for ATP-driven indoleamine 2,3-dioxygenase 1 induction through P2Y11 receptor 47
Induction of regulatory T Cells by dendritic cells through indoleamine 2,3-dioxygenase: a potent mechanism of acquired peripheral tolerance 2
Totale 5.872
Categoria #
all - tutte 15.720
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.720


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021118 0 0 0 0 0 0 0 0 0 0 0 118
2021/2022620 28 26 43 33 71 35 10 56 28 42 141 107
2022/2023847 120 132 51 103 46 73 36 57 134 12 52 31
2023/2024244 20 36 9 34 21 73 13 4 9 5 17 3
2024/2025749 40 124 43 56 118 48 40 28 15 67 41 129
2025/20261.952 124 142 132 166 199 122 203 108 446 196 62 52
Totale 5.872